Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

522
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
522
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

204
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
204
Blinding01:11

Blinding

4.1K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.1K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

328
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Equine platelet lysate exhibits bacteriostatic effects against gram-negative clinical bacterial isolates.

Journal of equine veterinary science·2025
Same author

Equine fecal microbiota response to short term antibiotic administration.

Journal of equine veterinary science·2024
Same author

Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis.

Archives of microbiology·2018
Same author

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2017
Same author

Clinical trial success rates of anti-obesity agents: the importance of combination therapies.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2015
Same author

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

European neurology·2014
Same journal

Compartment-specific miRNA-gene expression patterns in relapsing-remitting multiple sclerosis: Clinical blood and cerebrospinal fluid validation.

Multiple sclerosis and related disorders·2026
Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026
Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026
Same journal

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026
Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026
Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Reducing clinical trial risk in multiple sclerosis.

C D De Gasperis-Brigante1, J L Parker1, P W O'Connor2

  • 1Department of Biology, University of Toronto at Mississauga, University of Toronto, 3359 Mississauga Road, Mississauga, ON, Canada L5L 1C6.

Multiple Sclerosis and Related Disorders
|February 10, 2016
PubMed
Summary
This summary is machine-generated.

Clinical trials for multiple sclerosis (MS) drugs show a 27% success rate, nearly triple the industry average. Early phase trials in relapsing MS populations and small molecule drugs show higher success potential.

Keywords:
BiologicsClinical trial riskDisease modifying therapyMultiple sclerosisNew drug developmentSmall molecules

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Area of Science:

  • Neuroscience
  • Clinical Pharmacology
  • Drug Development

Background:

  • Multiple Sclerosis (MS) presents unique challenges for drug development.
  • Assessing clinical trial success rates is crucial for understanding drug development efficiency in MS.
  • Industry-wide benchmarks provide a comparative standard for evaluating specific therapeutic areas.

Purpose of the Study:

  • To evaluate the clinical trial failure risk for novel drugs targeting multiple sclerosis (MS).
  • To identify key factors influencing the success rates of MS drug development.
  • To compare MS clinical trial outcomes against general industry standards.

Main Methods:

  • Data compilation of compounds tested in MS clinical trials (Phase I-III) from 1998 to 2015.
  • Calculation of cumulative and phase-specific clinical trial success rates for MS drugs.
  • Comparative analysis against industry success rates, with defined exclusion criteria for drug candidates.

Main Results:

  • Fifty-three distinct drugs met inclusion criteria, yielding a 27% cumulative success rate for MS drugs.
  • MS clinical trial success rates significantly exceed the 10% industry average across all phases.
  • Phase II trials in relapsing MS populations best predicted Phase III success; small molecules outperformed biologics.

Conclusions:

  • Multiple sclerosis drug development demonstrates a significantly higher success rate (27%) compared to industry standards (10%).
  • Small molecule drugs show greater efficacy than biologics in MS clinical trials.
  • Novel drug candidates without prior FDA approval for other indications exhibit higher success rates in MS than repurposed drugs.